Trials / Completed
CompletedNCT00844285
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,072 (actual)
- Sponsor
- UCB BIOSCIENCES, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and it's objective is to monitor patients for approximately 8 years.
Detailed description
Physicians are expected to manage patients as they would under normal practice conditions; patients will receive and use their medications according to their normal course of medical treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cimzia | The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg. |
Timeline
- Start date
- 2009-01-30
- Primary completion
- 2020-08-21
- Completion
- 2020-08-21
- First posted
- 2009-02-16
- Last updated
- 2023-05-06
- Results posted
- 2023-05-06
Locations
197 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00844285. Inclusion in this directory is not an endorsement.